Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Yael L. Maxwell

November 27, 2024

Presentation TCT 2024

TCT 230: Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk: A Post-Hoc Analysis of the TWILIGHT Trial

Presenter: Mauro Gitto

October 27, 2024

Presentation TCT 2024

TCT 4: Rationale and Design of the IMODERN STOP-IMH Randomized Trial: The Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for STEMI and the Effect on Intramyocardial Haemorrhage

Presenter: Bahram Yosofi

October 27, 2024

Presentation TCT 2024

TCT 3: Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction (TIMO-AMI Study)

Presenter: Oskar Angerås

October 27, 2024

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

News Daily News

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

Caitlin E. Cox

June 25, 2024

News Daily News

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

Yael L. Maxwell

June 14, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Advertisement

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

TCT 230: Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk: A Post-Hoc Analysis of the TWILIGHT Trial

TCT 4: Rationale and Design of the IMODERN STOP-IMH Randomized Trial: The Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for STEMI and the Effect on Intramyocardial Haemorrhage

TCT 3: Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction (TIMO-AMI Study)

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

What’s Going to Be Hot at ACC 2024

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content